NDAORALFOR SUSPENSION
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POLYCILLIN-PRB is an oral suspension combining ampicillin (a beta-lactam antibiotic) with probenecid (a uricosuric agent that inhibits renal tubular secretion) to enhance ampicillin bioavailability and reduce dosing frequency. This combination is used to treat bacterial infections where elevated ampicillin serum levels are therapeutically advantageous. The probenecid component blocks renal excretion of ampicillin, thereby prolonging its half-life and improving clinical efficacy.
Pre-Launch
Pre-launch status indicates active development and preparation phases; team size and hiring likely ramping for launch readiness.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on POLYCILLIN-PRB during pre-launch offers exposure to product development, regulatory strategy, and commercialization planning at Bristol Myers Squibb. This is an opportunity to build foundational expertise in antibiotic portfolio management and oral dosage form launches.
Brand ManagerProduct Manager
Worked on POLYCILLIN-PRB at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.